[{"id":"d7a0703a-8b1b-461b-a082-3de4e2b533f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03061188","created_at":"2021-01-17T18:03:06.477Z","updated_at":"2025-02-25T14:37:19.874Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of Nivolumab \u0026 Veliparib in Patients With Advanced Solid Tumors \u0026 Lymphoma","source_id_and_acronym":"NCT03061188","lead_sponsor":"Northwestern University","biomarkers":" BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC","pipe":" | ","alterations":" MSI-H/dMMR • RAD50 mutation","tags":["BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAD50 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 03/11/2018","primary_completion_date":" 03/11/2018","study_txt":" Completion: 08/04/2020","study_completion_date":" 08/04/2020","last_update_posted":"2024-06-12"},{"id":"5c9cf0d2-4000-4d44-8b92-7009c77ded0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04187833","created_at":"2021-01-18T14:26:39.615Z","updated_at":"2024-07-02T16:35:28.977Z","phase":"Phase 2","brief_title":"Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes","source_id_and_acronym":"NCT04187833","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" TMB • BRCA1 • BRCA2 • BAP1 • MLH1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • PARP1 • CHEK1 • NBN • HDAC2 • EMSY • ERCC3 • PRKDC • LIG3","pipe":"","alterations":" ","tags":["TMB • BRCA1 • BRCA2 • BAP1 • MLH1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD50 • PARP1 • CHEK1 • NBN • HDAC2 • EMSY • ERCC3 • PRKDC • LIG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Talzenna (talazoparib)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 10/13/2023","primary_completion_date":" 10/13/2023","study_txt":" Completion: 10/13/2023","study_completion_date":" 10/13/2023","last_update_posted":"2023-11-16"},{"id":"94c45794-3c7a-4a80-9968-91c364190829","acronym":"","url":"https://clinicaltrials.gov/study/NCT03207347","created_at":"2021-01-18T15:48:36.731Z","updated_at":"2025-02-25T13:12:22.396Z","phase":"Phase 2","brief_title":"A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)","source_id_and_acronym":"NCT03207347","lead_sponsor":"University of Florida","biomarkers":" PTEN • IDH1 • IDH2 • ARID1A • BAP1 • CDK4 • CHEK2 • RAD51 • BRIP1 • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • CDK2 • WRN • RAD52 • BACH1 • FANCG • PRKDC • RPA1 • ABRAXAS1 • FEN1 • SLX4","pipe":" | ","alterations":" BARD1 mutation","tags":["PTEN • IDH1 • IDH2 • ARID1A • BAP1 • CDK4 • CHEK2 • RAD51 • BRIP1 • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • CDK2 • WRN • RAD52 • BACH1 • FANCG • PRKDC • RPA1 • ABRAXAS1 • FEN1 • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 08/30/2022","study_completion_date":" 08/30/2022","last_update_posted":"2023-09-15"}]